Suzanne Fields Jones
机构：Sarah Cannon · ORCID：0000-0001-6881-8050
发表论文 302 篇 · 总被引 10647 次 · h-index 46
代表论文
- Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours (2023 · British Journal of Cancer · 被引 38)
- A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors (2023 · Targeted Oncology · 被引 35)
- A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors (2023 · Investigational New Drugs · 被引 30)
- Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings (2022 · The Oncologist · 被引 30)
- A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer (2021 · Targeted Oncology · 被引 27)
- Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors (2021 · JCO Precision Oncology · 被引 19)